Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LNG Energy Announces Signing of Hydrocarbon Productive Participation Contracts (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Eiger BioPharmaceuticals Inc EIGR

Healthcare Biotechnology
Eiger BioPharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on the development of therapies for hepatitis delta virus (HDV) and other serious rare diseases. The Eiger HDV platform includes two therapies in phase III that target critical host processes involved in viral replication. Its clinical product candidates include Lonafarnib (LNF) for HDV, Peginterferon Lambda ... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:EIGR)

No current news is available.
View More News ››

Opinion & Analysis (NDAQ:EIGR)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:EIGR)

This is when you buy

@$5.15 ...
dragonfly454 - January 3, 2022

RE:200 Day Moving Average is 0.13 Cents Away!

Current high price on July 16, 2017 was 10.25 p/s while the 200 day moving average is 10.38 p/s. That is price difference of 0.13 cents...
stockflower - July 14, 2017

200 Day Moving Average is 0.13 Cents Away!

We are 0.13 cents away from the 200 day moving average! At that point everyone should be confident that share prices will be increasing...
stockflower - July 14, 2017

a

August 31 Deadline in Lawsuit for Investors in Celladon Corp (NASDAQ:CLDN) Shares Announced by Shareholders Foundation 25 Aug 2015...
Trader24 - September 3, 2015

a h

Trader24 - September 3, 2015
View more Bullboard ››

Bitget

Bitget

Bitget is a leading cryptocurrency exchange serving 20+ million users in 100+ countries and processing daily trading volume ...
View More »